A Study to Evaluate SAGE-217 in Participants With Bipolar I/II Disorder With a Current Major Depressive Episode

NCT03692910 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

35

Enrollment

INDUSTRY

Sponsor class

Conditions

Bipolar Disorder I
Bipolar Disorder II
Major Depressive Episode

Interventions

DRUG: SAGE-217
DRUG: Placebo

Sponsor

Biogen